Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2016
CADTH supports the use of Entyvio in Crohn's disease
31 October 2016 - Takeda's Entyvio clocks up another CADTH recommendation. ...
Posted by Michael Wonder on 31 Oct 2016
New Zealand Pharmaceutical Schedule - 1 November 2016 update
1 November 2016 - The November 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2016
Schedule of Pharmaceutical Benefits - 1 November 2016 update
1 November 2016 - The 1 November 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 31 Oct 2016
Otezla finally recommended for use by patients with psoriasis
25 October 2016 - Resubmission does better than initial submission. ...
Posted by Michael Wonder on 31 Oct 2016
CADTH recommends Epclusa
25 October 2016 - CADTH has recommended Gilead's new combination product for patients with chronic hepatitis C virus infection. ...
Posted by Michael Wonder on 31 Oct 2016
Proposal to list and award sole supply to celecoxib Pfizer
31 October 2016 - Following a request for proposals for the supply of selective cyclooxygenase-2 inhibitors of the ‘coxib’ class ...
Posted by Michael Wonder on 31 Oct 2016
Review of pharmacy remuneration and regulation
31 October 2016 - In his most recent Message from the Chair, Prof Stephen King has thanked all those who ...
Posted by Michael Wonder on 30 Oct 2016
CADTH recommends the reimbursement of Taltz
25 October 2016 - The CADTH CDEC has recommend that ixekizumab be reimbursed for patients with moderate to severe plaque ...
Posted by Michael Wonder on 30 Oct 2016
PBAC Drug Utilisation Sub Committee public release documents
28 October 2016 - The utilisation analysis public release documents from the June 2016 PBAC Drug Utilisation Sub Committee meeting are ...
Posted by Michael Wonder on 29 Oct 2016
Cancer Drugs Fund: the bigger picture
26 October 2016 - Carole Longson and others from NICE welcome the authors’ creative ideas on the appraisal of cancer ...
Posted by Michael Wonder on 28 Oct 2016
PBAC Public Summary Documents - July 2016 meeting
28 October 2016 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the July 2016 PBAC ...
Posted by Michael Wonder on 28 Oct 2016
Post-market review of ezetimibe – targeted stakeholder forum
28 October 2016 - The Reference Group of the Post-market Review of ezetimibe has requested that a targeted Stakeholder Forum ...
Posted by Michael Wonder on 28 Oct 2016
PHARMAC outlines changes at Tauranga public forum
27 October 2016 - Pharmac came to Tauranga yesterday to discuss proposed changes to improve how medicines and medical device funding ...
Posted by Michael Wonder on 28 Oct 2016
Update on proposed changes to 2nd & 3rd line anti-VEGF treatments for ophthalmic use
28 October 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) ...
Posted by Michael Wonder on 27 Oct 2016
New Zealanders to benefit from partnership to enhance responsible use of medicines
27 October 2016 - PHARMAC is pleased to announce a new partnership to support prescribing decisions and promote the responsible ...